Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma by Ghaffar, Shehzad et al.
eCommons@AKU
Section of Otolaryngology, Head & Neck Surgery Department of Surgery
March 2010
Comparison of different treatment modalities in










Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_surg_otolaryngol_head_neck
Part of the Otolaryngology Commons
Recommended Citation
Ghaffar, S., Ikram, M., Imam, S., Sepah, Y. (2010). Comparison of different treatment modalities in advanced laryngeal
hypopharyngeal squamous cell carcinoma. Journal of the College of Physicians and Surgeons Pakistan, 20(3), 171-4.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_otolaryngol_head_neck/2
Journal of the College of Physicians and Surgeons Pakistan  2010, Vol. 20 (3): 171-174 171
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is
the fifth most common cancer in men, with a worldwide
incidence of approximately 780,000 new cases per
year.1 It is widely spreading disease in Southeast Asia
due to increased use of tobacco. Among all the sites of
Head and Neck, oral cavity takes the lead followed by
larynx and hypopharynx.2
Hypopharyngeal cancers are usually squamous cell
carcinomas (SCCs) that has the worst prognosis among
the head and neck cancers. Overall, 5-year survival rate
remains poor despite recent advancements in diagnostic
imaging, radiation, chemotherapy and improved surgical
techniques. Hypopharyngeal cancers tend to present in
advanced stage, and nodal metastasis is mostly present
at initial presentation. The most important features
determining prognosis are the size and extent of local
spread of the primary carcinoma and the extent of
involvement of regional lymph nodes. Distant metastasis
at presentation is commonly seen in hypopharyngeal
cancers than in other head and neck cancers. Poor
survival is partly due to emergence of second primary
cancers but also secondary to development of distant
metastasis.3
Until the early 1990s, the standard treatment for locally
advanced disease was total laryngectomy followed by
radiation.4 Induction chemotherapy (cisplatin plus
fluorouracil) followed by radiotherapy, and surgery plus
adjuvant radiotherapy for advanced laryngeal hypo-
pharyngeal cancer shows comparable results.5
Decision of modality of treatment for advanced (stage-III
and IV) laryngeal/hypopharyngeal cancer needs
consideration to matters other than tumour type and
staging, like general health of the patient, socio-
economic status of the patient, patients understanding
the importance of regular follow-up and possibility of
salvage treatment either in the middle of chemoradiation
protocol or at its completion. Chemoradiation is frequently
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ORIGINAL ARTICLE
associated with serious toxicity, which is aggravated in
malnourished patients.6 Swallowing dysfunction is a
devastating complication of chemoradiation therapy
(CRT) for head and neck squamous cell carcinoma. Pre-
treatment swallowing exercises improve post-treatment
swallowing-related quality of life.7
Low socioeconomic status and uncommon practice of
medical insurance largely affects medical access of the
patient,8 Like other diseases, head and neck cancer is
commonly seen in patients belonging to low socio-
economic group and that also affects treatment
outcomes.8 The only disadvantage of surgical treatment
for advanced laryngeal hypopharyngeal cancer is a
permanent tracheostomy in the neck and loss of voice,
which can very well be taken care by conservative
laryngeal procedures, where applicable. 
The objective of this study was to compare disease free
outcome of patients with advanced laryngeal hypo-
pharyngeal squamous cell carcinoma treated either
surgically or with chemotherapy and/or radiotherapy.
METHODOLOGY
This was an observational study carried out at The Aga
Khan University Hospital between January 2000 until
December 2005. Patients were selected on a convenient
sampling method from Head and Neck cancer registry.
Medical records of already treated advanced stage (III
and IV) squamous cell carcinoma larynx/hypopharynx
patients were reviewed. Only those cases of advanced
larynx hypopharynx squamous cell cancer were
selected where treatment was offered with curative
intention and no prior treatment was acquired for this
disease. Out of 275 cases treated during this period,
119 cases were selected being stage-III and IV. Non-
squamous pathology and early laryngeal/hypopharyngeal
cancer were excluded from the study. Patient’s
treatment selection was biased depending where patient
presented, whether it be surgical clinic, radiation
oncologist or medical oncologist. 
Patients who underwent surgery alone or with adjuvant
therapy were placed in Group-A whereas patients who
received radiotherapy and/or chemotherapy were
categorized in Group-B by the investigators.
Data on demographic information, recurrence rate and
rate of larynx preservation was collected on a proforma.
Data was analyzed using SPSS 14. Frequencies by
groups (surgical and non-surgical) for gender, stages of
the disease, tumour location, neck metastasis, adjuvant
therapy and patterns of recurrence have been observed.
Kaplan Meier technique was used to estimate mean
recurrence time with standard errors. Graph of
recurrence rate was made for overall recurrence time,
tumour location and by groups. Cox proportional hazard
regression was also used to estimate the hazard ratio
with 95% confidence interval for gender, age and tumour
location.
RESULTS
One hundred nineteen patients were selected for this
review. Seventy four patients (62%) were in the surgical
group (group-A) and rest in the group-B. In both the
groups, mean ages of the patients were 59 years. There
were 69 males in group-A and 32 males in group-B. In
group-A, 46 patients (62%) were stage-III whereas in
group-B, 22 patients (49%) were stage-III. Forty nine
patients in the group-A had lesion limited to larynx only,
3 patients had lesion limited to hypopharynx and 22
patients had lesion involving both larynx and
hypopharynx. Ten patients in the group-B had lesion
limited to larynx only, 20 patients had lesion limited to
hypopharynx and 15 patients had lesion involving both
larynx and hypopharynx. Ipsilateral neck node involve-
ment was seen in 16 patients (22%) of the group-A out
of which 13 patients underwent neck dissection along
with surgery for primary disease. Twenty one patients
(47%) of group-B had neck metastasis, out of which 13
patients (29%) had ipsilateral and 8 patients (18%) had
contralateral metastasis. In group-A, 30 patients (40%)
also received postoperative adjuvant therapy, 27
patients (36%) received radiotherapy and 3 patients
(4%) received postoperative chemotherapy. In group-B,
45% received concomitant chemoradiation and the rest
received single modality treatment either radiation or
chemotherapy.  
Overall censoring was 47%. Mean follow-up duration
was 18.3 months. Mean recurrence time was 1369
± 193 days. In group-A, mean recurrence time was 2097
± 277 days. On the other hand in group-B, mean
recurrence time was 399 ± 68 days. Significant
difference in recurrence time was observed in both the
groups (p < 0.001, Figure 1). There is no difference in
recurrence time for different tumour locations (Figure 2).
The hazard ratio of recurrence in hypopharyngeal
tumours was 1.5 times (95% CI 0.68, 3.30) as compared
to tumours of larynx. Hazard ratio of recurrence was
1.98 times (95% CI 0.99-3.95) when both larynx and
hypopharynx were involved as tumour is localized to
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Figure 1:  Surgical vs. non-surgical recurrence pattern.
 
larynx only in Table I. No significant difference in the
recurrence was observed by gender, although females
had higher chance of recurrence as compared to males
(hazard ratio=1.15; 95% CI 0.49-2.67). Similarly, in
consideration of age, chances of recurrences were
higher in patients younger than 40 years of age but this
difference was also not statistically significant (hazard
ration 2.72; 95% CI 0.99 7.48, Table II).
In group-A, no patient had residual disease at the
completion of treatment and 21 patients (28%) later
developed locoregional recurrence. On the other hand
28 patients (62%) of the group-B had residual disease at
the completion of treatment. Out of those 28 patients,
10 patients died during treatment and rest of them were
lost to follow-up because of no improvement in their
disease process. Locoregional recurrence was observed
in 5 patients (11%) and larynx was retained in 12
patients (25 %) in group-B.
DISCUSSION
Laryngeal cancer for males has been reported in
Karachi as highest in Asia.2 Increase use of tobacco
either in the form of cigarette smoking or chewing
smokeless tobacco is regarded as the reason for this
high incidence. Bhurgari has reported 36% males and
44% females chew pan or pan with tobacco in Southern
Karachi,2 while in this study, 85% of the patients
were male.
Cervical node metastasis is frequently encountered in
larynx and hypopharyngeal tumours. Buckley and others
have noticed 36% of ipsilateral and 27% of contralateral
nodal metastases in surgical specimen for no neck and
rate was 90% and 37%, respectively in N+ necks.9 In
this series, overall neck node involvement was noticed in
32% cases, 23% had ipsilateral neck node involvement
and 9% had contralateral neck metastasis. 
Bova and others evaluated patients with total laryngo-
pharyngectomy in the treatment of hypopharyngeal
cancer squamous cell carcinoma.10 Thirty one (17.8%)
and 43 (24%) patients developed locoregional and
distant metastasis respectively. Two and 5 years disease
specific survival rates were 72 and 52%, respectively.
Univariate analysis shows advanced nodal stage,
perineural invasion, lymphovascular invasion, and
positive margins as predictors of poor survival and
lymphovascular invasion was an independent prognostic
factor on multivariate analysis.10
Byers and others have reported improved survival in
patients who received postoperative radiotherapy in the
management of laryngeal cancer.11 In group-A of this
series, 40% received postoperative adjuvant therapy.
Single modality treatment for advanced laryngeal and
hypopharyngeal cancer is not widely accepted but is still
practiced. Haugen and others used radiotherapy for
advanced (T3 and T4) laryngeal cancer with or without
chemotherapy. He  reported an overall poor outcome of
the disease but more importantly his results have
revealed no change in outcome whether chemotherapy
was combined or not with radiotherapy.12 Similarly, in
group-B of this study, 45% received concomitant
chemoradiation and the rest received single modality
treatment with no change in outcome.
Lohynska et al. has reported median follow-up time of 36
months.13 In this series, the mean follow-up duration
was only 18.3 months. Poor follow-up is attributed to
lack of financial recourses, poor understanding of the
importance of follow-up on patient’s part and patients
belonging to remote areas outside the city. 
Stoeckli et al. have reported mean recurrence time for
laryngeal cancer after radiotherapy as 14.5 months (435
days) and 10.6 months (318 days) for hypopharyngeal
cancers.14 In this series, mean recurrence time of all the
patients was 46 months, while mean recurrence time in
group-A was 70 months and mean recurrence time for
group-B was 13 months. Gleich and others reported 48
recurrences in their series of 940 stage T3 or T4
squamous cell cancer patients.15 Twenty four patients
developed primary site recurrence, 20 patients developed
regional recurrence, and 4 patients developed locoregional
recurrence. Mean time for recurrence was 14.0 months
and the mean survival time was 26.2 months. Survival is
poor once recurrence is noted after treatment for
advanced primary site head and neck cancer.15
Lohynska et al. reported worse prognosis in females as
compared to males and in their series, age had no
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Table I: Hazard ratio of recurrence with tumour location.
Tumour location Mean recurrence Hazard ratio
time (SE) (95% CI)
Only larynx 2030.4 (329.8) 1
Only hypopharynx 468.1 (105.5) 1.50 (0.68, 3.30)
Both larynx and hypopharynx 753.4 (179.0) 1.98 (0.99, 3.95)
Figure 2:  Recurrence pattern with tumour location.
Table II: Hazard ratio of recurrence with age.
Age group Mean recurrence Hazard ratio 
time (SE) (95% CI)
< 40 280.2 (86.4) 2.72 (0.99, 7.48)
41-50 886.6 (183.0) 0.69 (0.24, 2.01)
51-60 1069.4 (268.1) 1.06 (0.49, 2.30)
61-70 1816.8 (344.7) 0.74 (0.34, 1.62)
71 and above 911.7 (242.3) 1
bearing on outcome.13 Similarly, in this series, chances
of recurrences were higher in females as compared to
males but chances of recurrences were higher in
patients younger than 40 years of age as compared to
patients with age more than 40 years. 
Timely identification of recurrence is essential to plan
salvage treatment. In cases of advanced laryngeal
hypopharyngeal cancers managed non-surgically,
repeated CT scans/diffusional MRI are done to identify
recurrences. It is difficult to differentiate between
recurrence and radionecrosis on computed tomography
scan and conventional magnetic resonance imaging.16
Diffusion weighted MRI or FDG PET are showing
promising results in identifying early recurrence.
Sensitivity, specificity, positive predictive value, and
negative predictive value of FDG-PET scanning are
reported as 100%, 81%, 46%, and 100%, respectively.17
Urba et al. has reported 30% residual disease in non-
surgical management of advanced laryngohypo-
pharyngeal cancer, twenty percent of which was
identified in the early part of treatment and underwent
early salvage surgery, 3% had late salvage surgery after
completion of chemoradiotherapy.18 In this series, 62%
of group-B had residual disease out of which 22% died
during the treatment and rest 40% were lost to follow-up
because of no response to treatment. Those 11% of the
patients who had locoregional recurrence, 7% were given
palliative chemotherapy because of late identification of
recurrence and only 4% could be offered salvage
surgery. Salvage surgery for recurrence after non-
surgical management of advanced larynx-hypopharynx
cancer ranges between 7-10%,18,19 similarly, in this
series salvage surgery was only possible in 4% of
patients. If repeated examinations under anaesthesia
and biopsies or FDG PET scan would be available,
these non-responders to treatment could be timely
identified and salvage treatment could be possible. 
Limitations of this study were small sample size and bias
in selection of treatment, which in turn was influenced by
patient’s presentation.
CONCLUSION
There was significant difference in disease free outcome
when advanced larynx-hypopharynx cancer was
managed surgically as compared to non-surgical
management but at the expense of loss of voice and a
permanent stoma in the neck. Chances of retaining
larynx are only 25% when managed non-surgically.
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